Clinical Trial Update: CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 study of CPG10101 in relapsed hepatitis C patients, reporting safety and early signals of efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• CPG10101

Snippet

Sponsor: Pfizer | Conditions: Hepatitis, Chronic Active | Phase 1 | Status: COMPLETED